Finanzen von Bicycle Therapeutics PLC (BCYC)BCYCBicycle Therapeutics PLC

Evaluating the bottom line, Bicycle Therapeutics PLC maintains a gross margin of 96.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -53.76%, while the net margin is -30.77%. These profitability ratios, combined with a Return on Equity (ROE) of -25.24%, provide a clear picture of how effectively BCYC converts its operational activities into shareholder value.

In the context of the broader market, BCYC competes directly with industry leaders such as AMRN and ABEO. With a market capitalization of $260.36M, it holds a leading position in the sector. When comparing efficiency, BCYC's gross margin of 96.80% stands against AMRN's 40.91% and ABEO's 63.30%. Such benchmarking helps identify whether Bicycle Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Bicycle Therapeutics reported a Q3 2026 net loss of $10.48 million, a significant improvement from previous quarters, but still indicative of ongoing financial struggles. The gross margin is strong at 96.8%, but revenue has seen a steep decline, with Q2 revenue down 78.4% year-over-year.